Clermon

Quick links to important sections

Clermon

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clermon

Quick Facts

Property Description
Active ingredient Kallidinogenase (Human Urinary Kallidinogenase/HUK)
Form Tablet (enteric-coated) and Solution for injection/infusion
Pharmacological Class Peripheral Vasodilator; Serine Protease (Enzyme)
Typical Purpose Management of peripheral circulatory disturbances
Origin Biological Factor (Derived glycoprotein enzyme)

Defining Clermon: Classification and Active Ingredient

Clermon is a proprietary pharmaceutical product whose active ingredient is the enzyme Kallidinogenase, which is formally classified as a Peripheral Vasodilator and a Serine Protease enzyme. This classification defines the drug’s fundamental identity as an agent that works to facilitate the relaxation and widening of blood vessels in the microcirculation. The medicine's action is clinically recognized for its role in improving blood flow, characterized by the way this unique biological factor generally acts to support tissue health by enhancing blood delivery.

Composition, Origin, and Distinctive Features

The active ingredient, Kallidinogenase, is a high-molecular-weight glycoprotein enzyme derived from a biological factor, structurally related to the kallikrein enzyme found naturally in the body. This enzyme component gives the drug its high specialization. Clermon is available as a single active ingredient product in two primary preparation forms. The distinct enteric-coated tablet form is a key feature, as this specialized coating is necessary to protect the enzyme's sensitive protein structure from degradation by stomach acid during oral ingestion. It is also available as a sterile solution for injection for acute needs.

Clermon's General Purpose and Basic Function

The overarching purpose of Clermon is to improve blood flow and enhance microcirculation by acting as a bradykinin releaser within the body, which supports the function of tissues that rely on a steady blood supply, such as in typical use scenarios involving peripheral circulatory disturbances. The mechanism involves Kallidinogenase enzymatically converting a precursor protein (kininogen) into potent vasoactive peptides, such as bradykinin. This focused action results in targeted vasodilation at the microcirculatory level, increasing the efficiency of local blood flow.

What side effects are possible with Clermon?

The official safety documentation for Clermon (Kallidinogenase) is structured around categories of adverse reactions and defined safety constraints, primarily based on data from government-cited clinical studies.

Adverse Reaction Scope and Classification

The most frequently reported adverse event is transient hypotension, which is a temporary reduction in blood pressure and is consistently noted in regulatory documents due to the drug's intended peripheral vasodilator activity. Other adverse events, classified across System-Organ Classes, have included instances of constipation (Gastrointestinal Disorders) and changes in specific enzyme levels, such as an increase in Alanine Aminotransferase (ALT), indicating potential effects on Hepatobiliary function.

Serious Adverse Reactions and Safety Constraints

Official regulatory data tracks the incidence of Serious Adverse Events (SAEs) in trial populations. As a protein-derived product, there is a documented potential for allergic-type hypersensitivity reactions, which includes the risk of severe reactions such as anaphylaxis.

Specific safety restrictions define the appropriate use of Clermon. Regulatory documents consistently cite conditions that preclude treatment, including known allergy or intolerance to Kallidinogenase itself. Furthermore, official safety information indicates constraints related to existing severe medical conditions, such as severe renal dysfunction or severe hepatic dysfunction, and it is generally restricted for use in pregnant or lactating women.

Overdose and Emergency Response

The official regulatory profile for Clermon overdose focuses on the consequences of its exaggerated pharmacological effect as a peripheral vasodilator. Overdose manifestations are documented to include profound hypotension, characterized by a significant drop in blood pressure, often accompanied by compensatory tachycardia and generalized flushing. Patients may also experience dizziness or vertigo, signs secondary to reduced cerebral perfusion.

A Clermon overdose carries the risk of severe, life-threatening outcomes, principally circulatory collapse resulting from persistent and severe hypotension. The official documentation mandates that individuals seek immediate medical attention for any suspected overdose or immediately contact emergency services upon observing signs of profound hemodynamic instability.

Regulatory authorities confirm that no specific antidote is known for Clermon overdose. Consequently, the established procedural step for management involves administering symptomatic and supportive treatment designed to maintain vital physiological functions and stabilize the patient. Continuous cardiovascular monitoring is a required element of care during the post-overdose period until the patient's condition is fully stabilized. This mandated action underscores the serious nature of overdose and the necessity for urgent, dedicated hospital observation.

Therapeutic Uses of Clermon

Quick Facts

  • Clermon is utilized in the management of Condition A.
  • Clermon is designated to assist with the symptom management of a certain chronic issue.
  • It is used in a therapeutic regimen to support improved functioning in individuals with the designated health concern.

Clermon is an authorized medication intended for the treatment of specific medical conditions. Its primary use involves the management of Condition A in adult and pediatric patient populations, as determined by a healthcare provider. The drug may be incorporated into a comprehensive care plan to contribute to the stabilization of this condition.

Additionally, Clermon is applied in therapeutic domains to aid in the symptomatic relief of a related Chronic Issue. This treatment approach is designed to offer support for those experiencing particular manifestations of the illness. The clinical goal of treatment with Clermon is to help maintain an acceptable level of health within the specific limits of the labeled indications. It is generally used as part of an overall health management strategy and may be used in conjunction with other authorized treatments.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Clermon (Kallidinogenase) is defined by mandatory exclusion criteria documented in government-approved prescribing information and clinical protocols, limiting its use to specific populations.

Classification Rule Statement
Populations for whom use is allowed Established for the adult population, defined as individuals Age ge 18 years.
Populations for whom use is contraindicated Patients with known allergy or intolerance to Kallidinogenase. Individuals with active hemorrhagic diseases (e.g., cerebral hemorrhage), systemic bleeding, or coagulation dysfunction (e.g., thrombocytopenia).
Age-related eligibility rules Use is not established or excluded for the pediatric population (individuals under 18 years old).
Pregnancy and lactation eligibility status Explicitly contraindicated for use in both pregnant and lactating (breastfeeding) women.
Condition-specific eligibility rules Use is restricted in cases of severe liver dysfunction or severe kidney dysfunction, often defined by specific regulatory thresholds for biomarkers (e.g., ALT/AST or serum creatinine).
Eligibility-related restrictions Patients taking Angiotensin-Converting Enzyme Inhibitors (ACEI) within a defined timeframe are ineligible. Women of child-bearing age must be using effective contraception.

The official eligibility criteria impose strict restrictions on use related to a patient’s bleeding risk, organ function capacity, and reproductive status. Eligibility is limited to adult patients who do not present with these documented comorbidities or conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Clermon (Kallidinogenase) is subject to specific pharmacodynamic interactions as documented in government regulatory prescribing information. The official profile primarily involves additive effects with other agents affecting blood pressure and coagulation.


Documented Interaction Patterns

Interacting Product Category Official Interaction Classification Resulting Interaction Constraint
Antihypertensive Drugs & ACE Inhibitors Pharmacodynamic Reinforcement Increased risk of hypotension due to additive blood pressure-lowering effects.
Anticoagulants & Antiplatelet Agents Increased Risk Interaction Potential for augmented risk of bleeding or hemorrhage.
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Reduced Therapeutic Effect May diminish the therapeutic efficacy of Kallidinogenase.

Interaction Status and Restrictions

  • Contraindicated Combinations: No specific medicinal product combinations are formally labeled as contraindicated (strictly prohibited) in the reviewed regulatory documentation.
  • Timing Separation Rules: No mandatory dose separation or timing restrictions (e.g., "administer X hours apart") are explicitly stated in the official prescribing information.
  • Other Interactions: No official regulatory statements document specific interactions mediated by CYP-450 metabolism, drug transporters, food, alcohol, herbal products, or supplements. No population-specific interaction cautions are officially documented.

Mechanism of Action

How Clermon Works

Clermon operates through the Kallikrein-Kinin System (KKS), initiating a cascade of events that modulates local vascular resistance. The drug's mechanism is driven solely by its enzymatic function within this pathway.


Enzymatic Generation of Vasoactive Peptides

The active ingredient, Kallidinogenase, acts as a serine protease enzyme. This enzyme cleaves the endogenous protein Kininogen to release active Bradykinin peptides. This generation of Bradykinin establishes a localized concentration of the primary effector molecule that modulates vascular tone.


Endothelium-Driven Microvascular Relaxation

Bradykinin functions as an agonist by binding to the Bradykinin B2 Receptor ( B2 R) found on the vascular endothelium. This receptor activation triggers a signaling sequence that leads to the release of key physiological vasodilators, particularly Nitric Oxide (NO) and Prostacyclin ( PGI2). These mediators diffuse to the underlying smooth muscle, causing it to relax and resulting in the widening of the microvascular diameter and increased regional blood flow.

Dosage and Administration Information

How to Use Clermon

Clermon (Kallidinogenase) is used according to specific, standardized instructions that define the administration route, dosage, and frequency. Usage protocols often distinguish between the oral tablet and the solution for infusion.


Administration Details

Entity Official Administration Guideline
Route of Administration Oral (as a tablet) and Intravenous Infusion (IV) (as a solution).
Dosing Schedule Oral: Typically 10 to 50 units per dose, administered three times a day. IV (Acute Use): Standard dose is 0.15 PNA unit administered once daily.
Frequency Pattern Oral: Three times a day (TID). IV: Once a day (QD).
Special Condition (Oral) The tablet is enteric-coated and must be swallowed whole without chewing or cracking to ensure the drug is protected until proper absorption.
Special Condition (IV) The solution must be diluted and administered via slow intravenous infusion over a period of not less than 50 minutes.

Usage Structure and Duration

Treatment with the oral tablet generally follows a long-term maintenance pattern, with the dose potentially adjusted according to age and the patient's symptoms. The intravenous solution is typically used for a limited, acute course, often lasting 10 to 14 consecutive days. If an oral dose is missed, instructions advise skipping that dose if it is almost time for the next one, and never taking two doses at one time.

This form-specific protocol ensures standardized delivery of the enzyme, defining both the required rate of infusion and the conditions necessary for proper oral administration.

Recent Clinical Evidence

Clermon: Recent Clinical Evidence

The research evidence for Clermon (Kallidinogenase) primarily focuses on its evaluation in clinical contexts involving specific types of peripheral circulatory disturbances. This section summarizes the structure of the existing research, the outcomes that were measured, and the aspects that remain uncertain.


Evidence for Use in Acute Ischemic Stroke (AIS)

The research base largely relies on systematic reviews and meta-analyses that have consolidated data from multiple randomized controlled trials (RCTs). These studies was evaluated in adult patients who had recently experienced an Acute Ischemic Stroke (AIS). Research explored how neurological status and functional recovery was measured in patients receiving the medicine.

Researchers monitored outcomes reflecting daily functioning and neurological impairment, using scales like the National Institutes of Health Stroke Scale (NIHSS), and outcomes describing daily functioning or activity level, typically assessed by the Modified Rankin Scale (mRS). Studies monitored patterns in the observed populations receiving Kallidinogenase alongside standard care, comparing them to control groups. Research highlights changes measured during the study period related to neurological deficit scores.


Research on Post-Stroke Cognitive Function

Research exploring the medicine's role in Post-Stroke Cognitive Impairment (PSCI) was observed in some studies, primarily consisting of retrospective cohort studies. Outcomes related to functional imbalance were captured using cognitive assessment tools like the Montreal Cognitive Assessment (MoCA) score. Non-randomized evidence examining short-term symptom changes reported differences between the groups, and studies monitored changes in biomarkers during the observed time interval.


Evidence Gaps and Areas for Future Research

Clinical trials monitoring the use of Clermon followed patients over defined time intervals, with outcomes typically assessed at 90 days (three months). Follow-up durations were limited, meaning data for long-term outcomes are not fully established or consistently monitored.

The evidence quality varies across studies, and many systematic reviews conclude that further large-scale, high-quality, international randomized controlled trials are needed to strengthen the evidence base. Results apply only to the populations studied. Data for certain groups, such as children, remain insufficient, and a degree of methodological heterogeneity is noted among the various studies.

Key Studies & References

  1. Human urinary kallidinogenase decreases the incidence of post-stroke cognitive impairment in acute ischemic stroke patients

Frequently Asked Questions (FAQ)

Common questions about Clermon (FAQ)


Q: Does Clermon interact with common over-the-counter pain relievers like ibuprofen or aspirin?

Regulatory documents indicate that Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen and aspirin, may diminish the intended therapeutic effect of Clermon. The official product information indicates that taking these medicines together may potentially lessen Clermon's intended effect. Patients are generally advised to discuss all medications they are taking, including over-the-counter products, with their healthcare provider.


Q: Are there specific foods or drinks (like grapefruit juice or alcohol) that should be avoided while on Clermon?

Official regulatory information for Clermon does not document specific interactions with food or alcohol. Therefore, no mandatory dietary or alcohol restrictions are outlined in the official prescribing information for the general population. Specific concerns related to diet or alcohol should be discussed within the context of an individual's treatment plan.


Q: Does Clermon cause weight gain or loss, and how common is it?

According to the official product information and safety documentation, weight changes (either gain or loss) are not listed as a frequently reported adverse event of Clermon. Based on reported clinical data, weight changes are not identified as a common or frequently reported adverse event.


Q: How does Clermon affect sleep patterns?

Official regulatory information does not list insomnia, excessive drowsiness, or other sleep disturbances as frequently reported adverse events associated with the use of Clermon. Therefore, an effect on sleep patterns is not listed as a common side effect in the official product information.


Q: Are there any known drug interactions with common supplements like St. John's Wort or fish oil?

Official regulatory statements do not document specific interactions with common herbal products or supplements, including St. John's Wort or fish oil. This means there are no officially defined restrictions or cautions regarding the combination of Clermon with these products.


Q: How should Clermon be disposed of?

Unused or expired Clermon should be disposed of carefully according to official guidelines to prevent accidental use. The preferred method is typically to participate in a national drug take-back program or follow local instructions for disposal in the household trash, such as mixing it with an undesirable substance.


Q: Does Clermon affect the results of any common medical screening tests?

Official safety documentation notes instances of an increase in the enzyme Alanine Aminotransferase (ALT) in some patients. Since ALT is a common marker measured in liver function screening tests, the potential for changes in liver enzyme levels is information that is available to healthcare providers when interpreting test results.


Q: What is the expected duration of treatment with Clermon?

The expected duration depends on the form of the medication. The intravenous (IV) solution is typically used for a limited, acute course lasting 10 to 14 consecutive days. In contrast, the oral tablet generally follows a long-term maintenance pattern for chronic conditions.


Q: Can Clermon be used during the cold and flu season with common cold remedies?

Cold remedies often contain ingredients that are classified as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Since Clermon has a documented interaction with NSAIDs which may reduce its efficacy, the combination may require careful consideration when taking combination cold or flu products.


Q: Are there any long-term risks associated with Clermon use that are still being studied?

Due to limited follow-up periods in many clinical trials, data on very long-term outcomes and potential risks are not yet fully established or consistently monitored. The research indicates that follow-up was typically limited to periods such as 90 days.


Q: Does Clermon have any impact on fertility in men or women?

Clermon is contraindicated (not allowed) for use in pregnant women, and women of child-bearing age are typically required to use effective contraception while on the medication. While these restrictions apply, the official product information does not explicitly detail the drug's impact on male or female fertility itself.


Q: Why is Clermon typically prescribed in a specific formulation (e.g., tablet, capsule, liquid)?

Clermon is an enzyme, which is a sensitive protein. The oral tablet is specifically designed to be enteric-coated to protect the active ingredient from being degraded by the strong acid in the stomach. The solution for injection is used to deliver the drug directly into the bloodstream for acute medical needs.


Q: What are the safety precautions for handling Clermon (if applicable)?

Like all prescription medications, Clermon must be stored under specific conditions to maintain its quality and potency. It should be stored in its original container and must always be kept in a location out of the sight and reach of children and pets to prevent accidental ingestion.


Q: Is it possible to have an idiosyncratic reaction to Clermon?

The official safety profile for Clermon documents the potential for allergic-type hypersensitivity reactions. This includes the risk of severe, unpredictable immune responses, such as anaphylaxis, which is a serious adverse event documented in the safety profile.


Q: What is the half-life of Clermon in the body?

Pharmacokinetic studies have examined how long Clermon stays in the system. Following administration, the active substance has been observed to decline with multiple half-lives; for the longest phase, this is approximately 131 minutes based on available data.


Q: Is it normal to feel tired or dizzy when first starting Clermon?

The most frequently reported adverse event is transient hypotension, a temporary drop in blood pressure. This effect is a potential cause of symptoms like dizziness in some people. However, tiredness (fatigue) is not listed as a common or frequently reported side effect in the official safety documentation.


Q: Does Clermon affect driving ability or machine operation?

Due to the potential for side effects such as hypotension (low blood pressure) and related symptoms like dizziness, the official information advises caution. Given the potential for side effects that may affect concentration or motor skills, patients may need to exercise care when performing activities such as driving or operating machinery.


Q: What research or clinical trials support the use of Clermon?

The use of Clermon is supported by research, including randomized controlled trials and meta-analyses. These studies have primarily evaluated its effects on patients with Acute Ischemic Stroke (AIS), monitoring outcomes related to neurological function and functional recovery.


Q: How soon after stopping a non-Clermon medication is it safe to start Clermon?

Patients who have been taking certain restricted drugs, such as ACE Inhibitors, are often required to stop the medication before starting Clermon. In clinical trial protocols, this wait period has been defined as a minimum time equivalent to five half-lives of the specific drug that was stopped.


Q: Can Clermon be taken long-term, or is it only for short-term use?

Clermon is used for both short- and long-term treatment depending on the form and condition. The oral tablet formulation is generally used for long-term maintenance treatment. The intravenous solution, conversely, is typically reserved for a limited, acute course of treatment.


Q: Can taking Clermon impact my mood or mental clarity?

Official regulatory information and safety data do not list adverse events specifically related to changes in mood, mental clarity, or psychiatric disorders. Therefore, these types of effects are not documented as common side effects of the medication.


Q: What are the most common reasons people stop taking Clermon?

Clinical study reports note that patients may withdraw from treatment due to various reasons, including withdrawal of consent and experiencing Adverse Events (AEs). However, official product information does not explicitly identify a single 'most common reason' for stopping the drug across the general population.


Q: Are there any lab tests required before or during treatment with Clermon?

Official guidelines restrict Clermon's use in patients with severe liver or kidney dysfunction. Since these conditions are defined by specific blood markers like ALT/AST (liver enzymes) or serum creatinine (kidney function), these tests are often used to determine eligibility and to monitor safety during treatment.

How should Clermon be stored and disposed of?

Storage and Handling

Prescription medications such as Clermon must be stored under specific conditions to maintain their quality, strength, and purity, as defined by regulatory standards (e.g., FDA, EMA).

Mandatory Storage Requirements:

  • Store Clermon at the temperature specified on the product label, typically defined as Controlled Room Temperature (15°C to 30°C or 59°F to 86°F).
  • Keep the medicine in its original container and ensure the lid is tightly closed to protect it from moisture, light, or environmental exposure.
  • Always store the product in a location out of the reach of children and pets to prevent accidental ingestion.

Disposal of Unused Medicine

Disposal must follow official regulatory instructions. The preferred method for destroying unused or expired medicine is participating in a national drug take-back program or utilizing a DEA-authorized disposal site. If a take-back program is unavailable, consult the official guidelines regarding disposal in household trash, which typically requires mixing the medicine with an undesirable substance before sealing and discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clermon found in:

A-Z Index: